The epileptologist's perspective of focal cortical dysplasia type 3: From concept to management

The recent International League Against Epilepsy (ILAE) official and updated classification of focal cortical dysplasia (FCD) includes a third type-FCD type 3-characterized by architectural abnormalities (cortical dyslamination) associated with another "principal" lesion: hippocampal sclerosis (HS), developmental tumors, vascular malformations, or gliotic scars. We posit that the clinical relevance of FCD type 3 is not established, as dyslamination cannot be reliably identified preoperatively and (although unproven, because unidentifiable) persistence of cortical tissue with putative dyslamination after resective surgery does not preclude seizure control. Here we discuss these issues from the epileptologist's perspective and stimulate the debate on whether the FCD type 3 construct impacts decision-making in the epilepsy surgery field-or else is of little practical significance.

Authors

Institutions

Publication Details

Journal
Epilepsia
Published
2025-11-24
DOI
https://doi.org/10.1111/epi.70023
Primary Topic
Epilepsy research and treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The epileptologist's perspective of focal cortical dysplasia type 3: From concept to management

Francine Hehn de Oliveira, Thomas Frigeri, André Palmini, Eliseu Paglioli Neto et al.
Epilepsia
Epilepsy research and treatment
article

The epileptologist's perspective of focal cortical dysplasia type 3: From concept to management

Francine Hehn de Oliveira, Thomas Frigeri, André Palmini, Eliseu Paglioli Neto, Harvey B. Sarnat, Ricardo Paganin, Rafael Paglioli, Ricardo Bernardi Soder, William Alves Martins, Vicenzo Zarpellon, Fernanda Schuh
article en

Abstract

The recent International League Against Epilepsy (ILAE) official and updated classification of focal cortical dysplasia (FCD) includes a third type-FCD type 3-characterized by architectural abnormalities (cortical dyslamination) associated with another "principal" lesion: hippocampal sclerosis (HS), developmental tumors, vascular malformations, or gliotic scars. We posit that the clinical relevance of FCD type 3 is not established, as dyslamination cannot be reliably identified preoperatively and (although unproven, because unidentifiable) persistence of cortical tissue with putative dyslamination after resective surgery does not preclude seizure control. Here we discuss these issues from the epileptologist's perspective and stimulate the debate on whether the FCD type 3 construct impacts decision-making in the epilepsy surgery field-or else is of little practical significance.

EpilepsiaVol. 67(3)
Universidade Federal do Rio Grande do Sul (BR), Alberta Children's Hospital (CA), Instituto do Cérebro (BR), Pontifícia Universidade Católica do Rio Grande do Sul (BR)
Cleveland Clinic, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Openalex Percentile: Top 57%
Epilepsy research and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.